Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
9 6 6 6

+8 more TTM periods

ROE
26.02% 23.00% 18.12% 19.68%
ROA
11.31% 9.31% 7.87% 8.13%
ROIC
17.56% 17.90% 16.94% 16.64%
Return on Tangible Assets
19.11% 16.35% 12.03% 12.72%
Average Days of Receivables
70.37 68.54 69.67 66.90
Free Cash Flow per Share
3.83 5.54 4.97 5.79
Free Cash Flow
265.60 387.80 349.90 407.50
Capital Expenditures
(245.60) (231.50) (219.40) (126.00)
Other line items
Cash ROIC
9.14% 14.20% 11.00% 12.91%
Accounts Receivable Turnover
5.91 6.13 6.14 6.02
Accounts Payable Turnover
8.05 8.11 16.21 16.26
Inventory Turnover
1.90 1.86 1.74 1.61
Average Days of Payables
50.96 65.01 35.64 24.45
Days of Inventory on Hand
200.35 200.73 215.05 226.38
Tax Rate
(0.24) (0.25) (0.27) (0.21)
Research and Development Expense of Revenue
11.33% 11.42% 11.12% 10.74%
Selling, General and Administrative Expense of Revenue
42.86% 42.11% 43.02% 43.40%
Share Based Compensation of Revenue
2.55% 2.27% 2.32% 2.47%
Interest Coverage
8.77 7.81 7.98 8.25
Operating CF/Net income
1.36 2.05 2.30 2.17
Depreciation/Fixed assets
0.12 0.11 0.11 0.12
Capex/Depreciation
(2.47) (2.44) (2.43) (1.44)
Revenue per Share
44.06 41.45 38.50 35.84
Operating CF per Share
7.38 8.85 8.09 7.58
Capex per Share
(3.54) (3.31) (3.12) (1.79)
Capex to Sales
0.08 0.08 0.08 0.05

Fold the line items

Columns are period end dates